Evidence map›Paper›PMID 33070160›Full record

ArticleThe pharmacogenomics journal2021

Pharmacogenetic information in Swiss drug labels - a systematic analysis.

C Jeiziner, K Suter, U Wernli, J M Barbarino, L Gong, M Whirl-Carrillo, T E Klein, T D Szucs, K E Hersberger, H E Meyer Zu Schwabedissen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The pharmacogenomics journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. HLA-associated adverse drug reactions - scoping review.Clinical and translational science · 2021
    Article
  16. Article
  17. Severe Adverse Drug Reactions to Quetiapine in Two Patients CarryingInternational journal of molecular sciences · 2021
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

C Jeiziner *Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, 4001, Switzerland. chiara.jeiziner@unibas.ch.ORCID http://orcid.org/0000-0002-1132-0240
K Suter *European Center of Pharmaceutical Medicine, Faculty of Medicine, University of Basel, Basel, 4056, Switzerland.
U WernliPharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, 4001, Switzerland.
J M BarbarinoDepartment of Biomedical Data Sciences, Stanford University, Stanford, CA, 94305, USA.
L GongDepartment of Biomedical Data Sciences, Stanford University, Stanford, CA, 94305, USA.
M Whirl-CarrilloDepartment of Biomedical Data Sciences, Stanford University, Stanford, CA, 94305, USA.
T E KleinDepartment of Biomedical Data Sciences, Stanford University, Stanford, CA, 94305, USA.
T D SzucsEuropean Center of Pharmaceutical Medicine, Faculty of Medicine, University of Basel, Basel, 4056, Switzerland.
K E HersbergerPharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, 4001, Switzerland.
H E Meyer Zu SchwabedissenBiopharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, 4056, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Implementation of pharmacogenetics (PGx) and individualization of drug therapy is supposed to obviate adverse drug reactions or therapy failure. Health care professionals (HCPs) use drug labels (DLs) as reliable information about drugs. We analyzed the Swiss DLs to give an overview on the currently available PGx instructions. We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB. From 5979 hits, 2564 were classified as PGx-relevant affecting 167 substances. 55% (n = 93) were classified as "actionable PGx". Frequently, PGx information appeared in the pharmacokinetics section and in DLs of the anatomic group "nervous system". Unstandardized wording, appearance of PGx information in different sections and unclear instructions challenge HCPs to identify and interpret PGx information and translate it into practice. HCPs need harmonization and standardization of PGx information in DLs to personalize drug therapies and tailor pharmaceutical care.

Indexed as

Drug LabelingDrug-Related Side Effects and Adverse ReactionsHumansPharmaceutical PreparationsPharmacogeneticsPharmacogenomic TestingSwitzerlandPharmaceutical Preparations

Identifiers

PMID33070160
PMCPMC8292148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.